Publication: Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Date
Date
Date
Citations
Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Lebbe, C., Mangana, J., Ascierto, P. A., Johnson, D. B., Carlino, M., Menzies, A., & Long, G. (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer, 10(7), e004610. https://doi.org/10.1136/jitc-2022-004610
Abstract
Abstract
Abstract
Background: Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown. We aimed to determine the efficacy and safety of PD1 versus IPI +PD1 after BRAF/MEK inhibitors (BRAF/MEKi).
Methods: Patients with V600BRAF mutant metastatic melanoma treated with BRAF/MEKi who had subsequent PD1 versus IPI+PD1 at eight centers were included. The endpoints w
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Pires da Silva, Ines
- Zakria, Danny
- Ahmed, Tasnia
- Trojanello, Claudia
- Dimitriou, Florentia
- Allayous, Clara
- Gerard, Camille
- Zimmer, Lisa
- Lo, Serigne
- Michielin, Olivier
- Lebbe, Celeste
- Mangana, Johanna
- Ascierto, Paolo Antonio
- Johnson, Douglas B
- Carlino, Matteo
- Menzies, Alexander
- Long, Georgina
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Lebbe, C., Mangana, J., Ascierto, P. A., Johnson, D. B., Carlino, M., Menzies, A., & Long, G. (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer, 10(7), e004610. https://doi.org/10.1136/jitc-2022-004610
